Swiss diagnostic firm Roche has launched a new test called anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for the diagnosis of prostate cancer.

Intended for the use in laboratories, the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody is designed to detect α-methylacyl-CoA racemase (AMACR) in formalin-fixed, paraffin-embedded (FFPE) tissue sections.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The new tool is validated for use with a dual stain and VENTANA Basal Cell Cocktail (34ßE12+p63) to enable easy differentiation of morphologically difficult cases such as benign, atypical or cancerous on a single slide.

The in-vitro diagnostic (IVD) primary antibody can be used on the automated slide stainers of the VENTANA BenchMark IHC/ISH series.

“The anti-p504s (SP116) Primary Antibody is an important tool to aid clinicians in making a more accurate diagnosis with a smaller tissue sample.”

Roche Tissue Diagnostics head Ann Costello said: “As the second most common cancer in men, prostate cancer is a serious public health concern.

“The anti-p504s (SP116) Primary Antibody is an important tool to aid clinicians in making a more accurate diagnosis with a smaller tissue sample.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The prostate adenocarcinoma is reported to be easily identifiable with the increased expression of biomarker, p504s or α-methylacyl-CoA racemase (AMACR).

The use of p504s in a dual stain with the VENTANA Basal Cell Cocktail is claimed to decrease the need for several slides, which is considered to be beneficial during the availability of limited tissue samples, as is the case for prostate biopsies.

Founded in 1896, Roche currently operates in more than 100 countries.

The firm develops pharmaceutical and diagnostic products for oncology, immunology, infectious diseases, ophthalmology and central nervous system disorders.

Image: Prostate carcinoma dual stained with anti-p504s (SP116) Rabbit Monoclonal Primary Antibody in red, and VENTANA Basal Cell Cocktail (34ßE12+p63) in brown. Photo: courtesy of PRNewsFoto/Roche.